OncoMatch

OncoMatch/Clinical Trials/NCT04870944

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Is NCT04870944 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies FACT Complex-targeting Curaxin CBL0137 for diffuse midline glioma, h3 k27-altered.

Phase 1/2RecruitingChildren's Oncology GroupNCT04870944Data as of May 2026

Treatment: FACT Complex-targeting Curaxin CBL0137This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.

Check if I qualify

Extracted eligibility criteria

Cancer type

Diffuse Intrinsic Pontine Glioma

Glioblastoma

Tumor Agnostic

Non-Hodgkin Lymphoma

Disease stage

Metastatic disease required

Metastatic Malignant Neoplasm in the Central Nervous System

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: CBL0137 (CBL0137)

Patients must not have received prior exposure to CBL0137

Lab requirements

Blood counts

ANC >= 1000/uL; Platelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

Kidney function

Creatinine clearance or radioisotope GFR >= 70 mL/min/1.73 m^2 or a creatinine based on age/sex

Liver function

Bilirubin (sum of conjugated + unconjugated or total) <= 1.5 x ULN for age; SGPT (ALT) <= 135 U/L (ULN for SGPT is 45 U/L)

Cardiac function

Shortening fraction of >= 27% by echocardiogram or ejection fraction of >= 50% by gated radionuclide study; Corrected QT (QTC) < 480 msec

See inclusion criteria for full details on organ function requirements

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Children's Hospital of Alabama · Birmingham, Alabama
  • Phoenix Childrens Hospital · Phoenix, Arizona
  • Children's Hospital Los Angeles · Los Angeles, California
  • Children's Hospital of Orange County · Orange, California
  • UCSF Medical Center-Mission Bay · San Francisco, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify